Zhi Tong Cai Jing·2026-02-09 22:28Core Viewpoint - China Biologic Products (01177) is advancing its self-developed innovative drug TQB2102, a HER2 dual-target antibody-drug conjugate (ADC), through a Phase III clinical trial aimed at evaluating its efficacy and safety compared to chemotherapy in HER2 low-expressing recurrent/metastatic breast cancer patients [1][2] Group 1: TQB2102 Development and Clinical Trials - TQB2102 is designed using three core technological innovations to optimize efficacy and safety: dual-target design, cleavable linker, and optimized drug-antibody ratio (DAR) [1] - The Phase III clinical trial (TQB2102-III-01) has completed the enrollment of all participants [1] Group 2: Clinical Research Results - At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, TQB2102 demonstrated a 53.4% overall objective response rate (ORR) in previously treated HER2 low-expressing patients, with a notable 58.3% ORR in the 7.5 mg/kg group [2] - Among patients who had previously progressed on ADC treatment, 44.4% achieved a response after TQB2102 therapy [2] - Safety data indicated that grade 3 or higher treatment-related adverse events (TRAEs) included neutropenia (23.3%), leukopenia (20.6%), anemia (8.2%), and hypokalemia (6.9%), with overall tolerability being good [2] Group 3: Market Positioning and Strategy - The company has established a comprehensive portfolio in breast cancer treatment, covering various molecular subtypes including HER2+, HER2 low-expressing, HR+/HER2-, and triple-negative breast cancer, addressing the entire treatment continuum from neoadjuvant to adjuvant therapy [2]